379 related articles for article (PubMed ID: 27161438)
1. Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.
Kuhn C; Weiner HL
Immunotherapy; 2016 Jul; 8(8):889-906. PubMed ID: 27161438
[TBL] [Abstract][Full Text] [Related]
2. Otelixizumab in the treatment of type 1 diabetes mellitus.
Sprangers B; Van der Schueren B; Gillard P; Mathieu C
Immunotherapy; 2011 Nov; 3(11):1303-16. PubMed ID: 22053883
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD3 mAbs for treatment of type 1 diabetes.
Kaufman A; Herold KC
Diabetes Metab Res Rev; 2009 May; 25(4):302-6. PubMed ID: 19319985
[TBL] [Abstract][Full Text] [Related]
4. CD3-specific antibodies: a portal to the treatment of autoimmunity.
Chatenoud L; Bluestone JA
Nat Rev Immunol; 2007 Aug; 7(8):622-32. PubMed ID: 17641665
[TBL] [Abstract][Full Text] [Related]
5. Achieving antigen-specific tolerance in diabetes: regulating specifically.
Chen W; Bluestone JA; Herold KC
Int Rev Immunol; 2005; 24(5-6):287-305. PubMed ID: 16318983
[TBL] [Abstract][Full Text] [Related]
6. [One step towards restoration of self-tolerance in human autoimmune diseases].
Chatenoud L
Med Sci (Paris); 2007 Feb; 23(2):167-71. PubMed ID: 17291426
[TBL] [Abstract][Full Text] [Related]
7. Oral tolerance.
Weiner HL; da Cunha AP; Quintana F; Wu H
Immunol Rev; 2011 May; 241(1):241-59. PubMed ID: 21488901
[TBL] [Abstract][Full Text] [Related]
8. Induction of dominant tolerance using monoclonal antibodies.
Agua-Doce A; Graça L
Methods Mol Biol; 2007; 380():405-29. PubMed ID: 17876109
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH.
Ilan Y; Shailubhai K; Sanyal A
Clin Exp Immunol; 2018 Sep; 193(3):275-283. PubMed ID: 29920654
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive therapy of autoimmune diseases.
Bach JF
Immunol Today; 1993 Jun; 14(6):322-6. PubMed ID: 8104411
[TBL] [Abstract][Full Text] [Related]
11. Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases.
Dean Y; Dépis F; Kosco-Vilbois M
Swiss Med Wkly; 2012; 142():w13711. PubMed ID: 23254986
[TBL] [Abstract][Full Text] [Related]
12. The use of CD3-specific antibodies in autoimmune diabetes: a step toward the induction of immune tolerance in the clinic.
Chatenoud L
Handb Exp Pharmacol; 2008; (181):221-36. PubMed ID: 18071948
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody.
Ishikawa H; Ochi H; Chen ML; Frenkel D; Maron R; Weiner HL
Diabetes; 2007 Aug; 56(8):2103-9. PubMed ID: 17456848
[TBL] [Abstract][Full Text] [Related]
14. Antigen-specific induction of regulatory T cells for type 1 diabetes therapy.
Filippi C; Bresson D; von Herrath M
Int Rev Immunol; 2005; 24(5-6):341-60. PubMed ID: 16318986
[TBL] [Abstract][Full Text] [Related]
15. CD3-specific antibodies as promising tools to aim at immune tolerance in the clinic.
Chatenoud L
Int Rev Immunol; 2006; 25(3-4):215-33. PubMed ID: 16818372
[TBL] [Abstract][Full Text] [Related]
16. Targeting the TCR: T-cell receptor and peptide-specific tolerance-based strategies for restoring self-tolerance in CNS autoimmune disease.
Kohm AP; Turley DM; Miller SD
Int Rev Immunol; 2005; 24(5-6):361-92. PubMed ID: 16318987
[TBL] [Abstract][Full Text] [Related]
17. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.
Chatenoud L; Waldmann H
Rev Diabet Stud; 2012; 9(4):372-81. PubMed ID: 23804274
[TBL] [Abstract][Full Text] [Related]
18. Resetting the functional capacity of regulatory T cells: a novel immunotherapeutic strategy to promote immune tolerance.
Chatenoud L; Bach JF
Expert Opin Biol Ther; 2005 Sep; 5 Suppl 1():S73-81. PubMed ID: 16187942
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells in immune-mediated renal disease.
Ghali JR; Wang YM; Holdsworth SR; Kitching AR
Nephrology (Carlton); 2016 Feb; 21(2):86-96. PubMed ID: 26206106
[TBL] [Abstract][Full Text] [Related]
20. CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications.
Chatenoud L
Curr Opin Immunol; 2005 Dec; 17(6):632-7. PubMed ID: 16214320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
